{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T21:04:49Z","timestamp":1776891889466,"version":"3.51.2"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006168","name":"National Nuclear Security Administration","doi-asserted-by":"publisher","award":["DE-AC52\\u201307NA27344"],"award-info":[{"award-number":["DE-AC52\\u201307NA27344"]}],"id":[{"id":"10.13039\/100006168","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006168","name":"National Nuclear Security Administration","doi-asserted-by":"publisher","award":["LLNL-JRNL-857512"],"award-info":[{"award-number":["LLNL-JRNL-857512"]}],"id":[{"id":"10.13039\/100006168","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-20\\u20130-AL200115"],"award-info":[{"award-number":["W81XWH-20\\u20130-AL200115"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Digital Health"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.landig.2025.100963","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:53:54Z","timestamp":1773186834000},"page":"100963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of drug repurposing candidates for amyotrophic lateral sclerosis using electronic health records: a retrospective cohort study"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-4673","authenticated-orcid":false,"given":"Richard J","family":"Reimer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-708X","authenticated-orcid":false,"given":"Braden","family":"Soper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre R","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Cadena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy L","family":"Gryshuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin V","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadip","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.landig.2025.100963_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.landig.2025.100963_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075037","article-title":"Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis","volume":"383","author":"Ilieva","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.landig.2025.100963_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000126910","article-title":"The National Registry of Veterans with amyotrophic lateral sclerosis","volume":"30","author":"Allen","year":"2008","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.landig.2025.100963_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jocn.2017.08.035","article-title":"Military service and the risk of amyotrophic lateral sclerosis: a meta-analysis","volume":"45","author":"Tai","year":"2017","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.landig.2025.100963_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40261-024-01371-1","article-title":"Sodium phenylbutyrate and tauroursodeoxycholic acid: a story of hope turned to disappointment in amyotrophic lateral sclerosis treatment","volume":"44","author":"Ketabforoush","year":"2024","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.landig.2025.100963_bib6","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1474-4422(14)70129-2","article-title":"Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?","volume":"13","author":"Mitsumoto","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.landig.2025.100963_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/jnnp-2021-328470","article-title":"Review of disease-modifying drug trials in amyotrophic lateral sclerosis","volume":"93","author":"Tornese","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.landig.2025.100963_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1517\/14656566.7.2.195","article-title":"Thalidomide in multiple myeloma","volume":"7","author":"Garc\u00eda-Sanz","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.landig.2025.100963_bib9","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1097\/MJT.0000000000000766","article-title":"Sildenafil for pulmonary arterial hypertension","volume":"26","author":"Bhogal","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.landig.2025.100963_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.landig.2025.100963_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246825","article-title":"Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration","volume":"16","author":"Osborne","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.landig.2025.100963_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/acn3.51697","article-title":"Identification of potential pathways and biomarkers linked to progression in ALS","volume":"10","author":"Huber","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.landig.2025.100963_bib13","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1038\/srep08580","article-title":"Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records","volume":"5","author":"Paik","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.landig.2025.100963_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41746-022-00617-6","article-title":"Computational drug repurposing based on electronic health records: a scoping review","volume":"5","author":"Zong","year":"2022","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.landig.2025.100963_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s42256-020-00276-w","article-title":"A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data","volume":"3","author":"Liu","year":"2021","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.landig.2025.100963_bib16","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1038\/s41467-023-43929-1","article-title":"High-throughput target trial emulation for Alzheimer\u2019s disease drug repurposing with real-world data","volume":"14","author":"Zang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.landig.2025.100963_bib17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1021\/acschemneuro.8b00456","article-title":"Evidence of repurposing drugs and identifying contraindications from real world study in Parkinson\u2019s disease","volume":"10","author":"Tang","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.landig.2025.100963_bib18","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/psp4.12861","article-title":"A network paradigm predicts drug synergistic effects using downstream protein-protein interactions","volume":"11","author":"Wilson","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.landig.2025.100963_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21678421.2023.2239300","article-title":"An electronic health record cohort of veterans with amyotrophic lateral sclerosis","volume":"24","author":"Reimer","year":"2023","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.landig.2025.100963_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1478-7954-4-2","article-title":"Accuracy and completeness of mortality data in the Department of Veterans Affairs","volume":"4","author":"Sohn","year":"2006","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.landig.2025.100963_bib21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1037\/h0037350","article-title":"Estimating causal effects of treatments in randomized and nonrandomized studies","volume":"66","author":"Rubin","year":"1974","journal-title":"J Educ Psychol"},{"key":"10.1016\/j.landig.2025.100963_bib22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/sim.2580","article-title":"A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study","volume":"26","author":"Austin","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.landig.2025.100963_bib23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.landig.2025.100963_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.landig.2025.100963_bib25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.landig.2025.100963_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"key":"10.1016\/j.landig.2025.100963_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006614","article-title":"PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development","volume":"14","author":"Wilson","year":"2018","journal-title":"PLOS Comput Biol"},{"key":"10.1016\/j.landig.2025.100963_bib28","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.landig.2025.100963_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28948-z","article-title":"GOATOOLS: a Python library for gene ontology analyses","volume":"8","author":"Klopfenstein","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.landig.2025.100963_bib30","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-018-05116-5","article-title":"Network-based approach to prediction and population-based validation of in silico drug repurposing","volume":"9","author":"Cheng","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.landig.2025.100963_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13195-021-00951-z","article-title":"Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer\u2019s disease","volume":"14","author":"Fang","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.landig.2025.100963_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10331","article-title":"Network-based in silico drug efficacy screening","volume":"7","author":"Guney","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.landig.2025.100963_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/ph11030061","article-title":"Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology","volume":"11","author":"Aguirre-Plans","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.landig.2025.100963_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.landig.2025.100963_bib56","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000002465","article-title":"Depression in ALS in a large self-reporting cohort","volume":"86","author":"Thakore","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.landig.2025.100963_bib34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.mehy.2011.01.021","article-title":"Can vitamin D delay the progression of ALS?","volume":"76","author":"Karam","year":"2011","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.landig.2025.100963_bib35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jnr.10483","article-title":"Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons","volume":"71","author":"Nakamizo","year":"2003","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.landig.2025.100963_bib36","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ana.26600","article-title":"Protective effects of lovastatin in a population-based ALS study and mouse model","volume":"93","author":"Kreple","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.landig.2025.100963_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104202","article-title":"Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis","volume":"83","author":"Chaytow","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.landig.2025.100963_bib38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.10374","article-title":"Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS","volume":"52","author":"Drachman","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.landig.2025.100963_bib39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1566-0702(01)00217-X","article-title":"Effect of tamsulosin hydrochloride on sympathetic hyperactivity in amyotrophic lateral sclerosis","volume":"88","author":"Ohno","year":"2001","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.landig.2025.100963_bib40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archneur.1979.00500470085019","article-title":"Trial of baclofen in amyotrophic lateral sclerosis","volume":"36","author":"Norris FH Jr, U KS","year":"1979","journal-title":"Arch Neurol"},{"key":"10.1016\/j.landig.2025.100963_bib41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1212\/WNL.56.7.843","article-title":"Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis","volume":"56","author":"Miller","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.landig.2025.100963_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00002826-199619020-00009","article-title":"A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis","volume":"19","author":"Blin","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.landig.2025.100963_bib43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.landig.2025.100963_bib44","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.landig.2025.100963_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.1997.tb00231.x","article-title":"A clinical trial of dextromethorphan in amyotrophic lateral sclerosis","volume":"96","author":"Gredal","year":"1997","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.landig.2025.100963_bib46","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1093\/brain\/awac025","article-title":"Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts","volume":"145","author":"Goutman","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.landig.2025.100963_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj0264","article-title":"Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS","volume":"14","author":"Hop","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.landig.2025.100963_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/jnnp-2021-327133","article-title":"Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis","volume":"93","author":"Thompson","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.landig.2025.100963_bib49","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/pds.1643","article-title":"An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA\u2019s spontaneous adverse event reporting system","volume":"17","author":"Colman","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.landig.2025.100963_bib50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40264-017-0620-4","article-title":"Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA\u2019s adverse event reporting system","volume":"41","author":"Golomb","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.landig.2025.100963_bib51","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/jon.12993","article-title":"Autonomic dysfunction in amyotrophic lateral sclerosis: a neurophysiological and neurosonology study","volume":"32","author":"Papadopoulou","year":"2022","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.landig.2025.100963_bib52","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1007\/s00415-023-11832-w","article-title":"Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: a prospective longitudinal cohort study","volume":"270","author":"Dubbioso","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.landig.2025.100963_bib53","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.landig.2025.100963_bib54","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Writing","year":"2017","journal-title":"Lancet Neurol"}],"container-title":["The Lancet Digital Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589750025001451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589750025001451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:31:47Z","timestamp":1776889907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589750025001451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2589750025001451"],"URL":"https:\/\/doi.org\/10.1016\/j.landig.2025.100963","relation":{},"ISSN":["2589-7500"],"issn-type":[{"value":"2589-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of drug repurposing candidates for amyotrophic lateral sclerosis using electronic health records: a retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Digital Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.landig.2025.100963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100963"}}